Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current data on vigabatrin].

C Casas-Fernández1

  • 1Sección de Neuropediatria, Hospital Universitario Virgen de la Arrixaca, Murcia, España. ccasas@forodigital.es

Revista De Neurologia
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Transition from child to adult epilepsy. Difficulties with an objective that cannot be delayed].

Revista de neurologia·2018
Same author

Long-term prognosis of childhood absence epilepsy.

Neurologia·2017
Same author

Drug-resistant epilepsy: current recommendations for diagnosis and treatment in Spain.

Neurologia (Barcelona, Spain)·2011
Same author

Consensus-recommended diagnostic and therapeutic guidelines for drug-resistant epilepsy in Spain (Consenso RATE-España).

Neurologia (Barcelona, Spain)·2011
Same author

[A descriptive study of neurocysticercosis in a tertiary care hospital].

Revista de neurologia·2008
Same author

[Clinical update on Hunter syndrome (MPS II). Introduction].

Revista de neurologia·2007

Vigabatrin is effective for infantile spasms and partial seizures, but requires careful risk-benefit assessment due to potential visual field defects. This analysis reviews its pharmacokinetics, pharmacodynamics, and safety profile.

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Therapeutics

Context:

  • Vigabatrin is an antiepileptic drug with established efficacy in specific seizure types.
  • Understanding its pharmacokinetic and pharmacodynamic properties is crucial for optimizing treatment.
  • Therapeutic options for epilepsy, particularly infantile spasms and partial seizures, often involve a balance of efficacy and adverse effects.

Purpose:

  • To analyze the pharmacokinetic and pharmacodynamic characteristics of vigabatrin.
  • To review the therapeutic indications and clinical usefulness of vigabatrin, especially in infantile spasms (West's syndrome) and partial epileptic syndromes.
  • To assess the adverse effects of vigabatrin, focusing on visual field defects and their proposed mechanisms.

Summary:

  • Vigabatrin exhibits specific pharmacokinetic and pharmacodynamic profiles relevant to its efficacy in treating certain epileptic conditions.

Related Experiment Videos

  • The drug is particularly useful for infantile spasms in West's syndrome and partial epileptic seizures.
  • Adverse effects, notably peripheral visual field changes, necessitate a careful evaluation of risks versus benefits.

    • Impact:

    • This analysis aids clinicians in making informed decisions regarding vigabatrin use, balancing its benefits against potential risks.
    • Highlights the importance of monitoring for visual field defects in patients treated with vigabatrin.
    • Provides a comprehensive overview for healthcare professionals managing epilepsy, considering alternative treatments like corticosteroids or high-dose valproic acid.